Zusammenfassung
Der Diabetes mellitus Typ 2 ist durch eine Kombination von gestörter Insulinsekretion, Insulinresistenz und Hyperglykämie gekennzeichnet. Die Prävalenz dieser Stoffwechselstörung steigt in Abhängigkeit von Übergewicht und Adipositas stark an.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Literatur zu Abschn. 4.1
Cervera A, Wajcberg E, Sriwijitkamol A et al. (2008) Mechanisms of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294: E846–E852
DeFronzo RA (2009) Banting lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773–795
Harder T, Rodekamp E, Schellong K et al. (2007) Birth weight and subsequent risk of type 2 diabetes: a meta-analysis. Am J Epidemiol 165: 849
Hu FB, Li TY, Colditz GA, Willett WC, Manson JE (2003) Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 289: 1785–1791
Lyssenko V, Laakso M (2013) Genetic screening for the risk of type 2 diabetes. Diabetes Care 36 S2: S120–S126
Matsuda M, Liu Y, Mahankali S, Pu Y et al. (1999) Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 48: 1801–1806
Stefan N, Häring HU (2013) Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19: 394–395
Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabet es: principles of pathogenesis and therapy. Lancet 365: 1333
Literatur zu Abschn. 4.2
Brownlee M (2001) Biochem istry and molecular cell biology of diabetic comp lications. Nature 414(6865): 813–820
Kacerovsky-Bielesz G, Kacerovsky M et al. (2012) A single nucleotide polymorphism associates with the response of muscle ATP synthesis to long-term exercise training in relatives of type 2 diabetic humans. Diabetes Care 35(2): 350–357
Patti ME, Corvera S (2010) The ro le of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31(3): 364– 395
Petersen KF, Befroy D et al. (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300(5622):1140–1142
Szendroedi J, Phielix E et al. (2011) The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 8(2): 92–103
Timmers S, Konings E et al. (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14(5): 612–622
Literatur zu Abschn. 4.3
Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwège E (1998) High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21(3): 360–367
Barrett-Connor E, Ferrara A (1998) Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 21(8): 1236–1239
Black S, Kushner I, Samols D(2004) C-reactive Protein. J Biol Chem 279(47): 48487–48490
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 290(4): 486–494
De Vegt F, Dekker JM, Ruhé HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ (1999) Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42(8): 926–931
DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354(9179): 617–621
Donahue RP, Abbott RD, Reed DM, Yano K (1987) Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36(6): 689–692
Festa A, D’Agostino R Jr, Tracy RP, Haffner SM (2002) C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects; the Insulin Resistance Atherosclerosis Study. Diabet Med 19(11): 939–943
Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year followup. Diabetologia 39(12): 1577–1583
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004) Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25(1): 10–16
Jackson CA, Yudkin JS, Forrest RD (1992) A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract 17(2): 111–123
Landmesser U, Hornig B, Drexler H (2004) Endothelial function: a critical determinant in atherosclerosis? Circulation109 (21 Suppl 1): II27–33
Levitan EB, Song Y, Ford ES, Liu S (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease ? A meta-analysis of prospective studies. Arch Int Med 164(19): 2147–2155
Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grub M, Hombach V, Libby P, Zieske A, Homma S, Strong J (2004) C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 24(3): 540–545
Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW (2002) Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25(10): 1845–1850
Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26(3): 881–885
Raz I, Wilson PWF, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type-2 diabetes: The HEART2D trial. Diab Care 32(3): 381–386
Shaw JE1, Hodge AM, de Courten M, Chitson P, Zimmet PZ (1999) Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42(9): 1050–1054
Walcher D, Aleksic M, Jerg V, Hombach V, Zieske A, Homma S, Strong J, Marx N (2004) C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxinsensitive G-proteins and phosphoinositide 3-kinase. Diabetes 53(7): 1664–1670
Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115(5): 1111–1119
Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109(21 Suppl 1): II2–10
Literatur zu Abschn. 4.4
Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome – a new worldwide definition. Lancetr 366(9491): 1059–1062
Alberti KG, Eckel RH, Grundy SM et al. (2009) Harmonizing the metabolic syndrome. a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(06): 1640–1645
Giugliano D, Ceriello A, Esposito K (2008) Are there specific treatments for the metabolic syndrome? Am J Clin Nutr 87(1): 8–11
Grundy SM, Cleeman JI, Daniels SR et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112(17): 2735–2752
Hube F, Hauner H (1999) The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 31 (12): 626–631
Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 48(9): 1684–1699.
NCEP (2001) Expert panel on detection, evaluation, and treatment of high blood pressure in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). JAMA 285: 533–535
Sjöstrom L, Narbro K, SjöstromCD et al. (2007) Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357(8): 745–752
Stefan N, Stumvoll M (2002) Adiponectin – ist role in metabolism and beyond. Horm Metab Res 34(9): 469–474
UKPDS (1998) UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865
Literatur zu Abschn. 4.5
Bosch J et al. (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355(15): 1551–1562
Brawley LR, Rejeski WJ, King AC (2003) Promoting physical activity for older adults: the challenges for changing behavior. Am J Prev Med 25 (Suppl 2): 172–183
Buchanan TA (2007) (How) can we prevent type 2 diabetes? Diabetes 56(6): 1502–1507
Chiasson JL et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323): 2072–2077
DAK (2007) Abschlussbericht der Projektgruppe Diabetesprävention zum Modellprojekt der DAK zur Diabetesprävention in Sachsen. Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland, Berlin
DeFronzo RA et al. (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364(12): 1104–1115
Greaves CJ, Sheppard KE, Abraham C, Hardeman W, Roden M, Evans PH, Schwarz P, The IMAGE Study Group Peter. Schwarz@uniklinikum-dresden.de (2011) Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health 11: 119. doi:10.1186/1471-2458-11-119
Gruhl U et al. (2008) Prävention vor Kuration. Gesundheit 2010 – unsere Chance. Deutsche Diabetes Stiftung, München, p 74
Knowler WC et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6): 393–403
Kosaka K, Noda M Kuzuya T (2005) Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67(2): 152–162
Lindstrom J et al. (2003) Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the finnish diabetes prevention study: results from a randomized clinical trial. J Am Soc Nephrol 14 (7 Suppl 2): S108–113
Lindstrom J et al. (2010) Take action to prevent diabetes – the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 42 (Suppl 1): S37–S55
Pan XR et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4): 537–544
Paulweber B et al. (2010) A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 42(Suppl 1): S3–S36
Ramachandran A et al. (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49(2): 289–297
Schwarz PE, Peltonen M (2007) Prevention of type 2 diabetes – lessons we have learnt for implementation. Horm Metab Res 39(9): 636–641
Schwarz PE et al. (2007) The European perspective on diabetes prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE). Diab Vasc Dis Res 4(4): 353–357
Schwarz PE et al. (2012) Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nat Rev Endocrinol 8(6): 363–373
Snitker S et al. (2004) Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care 27(6): 1365–1368
Torgerson JS et al. (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1): 155–11
Trenell MI et al. (2008) Increased daily walking improves lipid oxidation without changes in mitochondrial function in type 2 diabetes. Diabetes Care, 2008 31(8): 1644–1649
Tudor-Locke CD, R Basset R Jr (2004) How many steps/day are enough? Preliminary pedometer indices for public health. Sports Med 34(1): 1–8
Tuomilehto J et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18): 1343–1350
Warburton DE, Nicol CW, Bredin SS (2006) Health benefits of physical activity: the evidence. CMAJ 174(6): 801–809
Wenying Y et al. (2001) The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17: 131–136
Yates T et al. (2011a) The Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: are improvements in glucose regulation sustained at 2 years? Diabet Med 28(10): 1268–1271
Yates T et al. (2011b) Stand up for your health: Is it time to rethink the physical activity paradigm? Diabetes Res Clin Pract 93(2): 292–294
Literatur zu Abschn. 4.6
Berger M et al. (1994) Behandlungs- und Schulungsprogramm für Typ-2-Diabetiker, die nicht Insulin spritzen. Deutscher Ärzte-Verlag, Köln
European Diabetes Policy Group (2000) European Diabetes Policy Group 1998–1999, International Diabetes Federation. Europäische Region: Leitfaden zu Typ-2-Diabetes mellitus. Diabetes Stoffw 9: 104–136
Füchtenbusch M, Standl E, Schatz H (2000) Clinical effficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 108: 151–163
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103(6): 491–497
Gerstein HC, Miller ME, Byington RP et al. (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24): 2545–2559
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15): 1577–1589
Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25(12): 2244–2248
Kulzer B, Hermanns N (2001) Mehr Diabetes-Selbstmanagement Typ 2: Ein neues Schulungs- und Behandlungsprogramm für Menschen mit nicht-insulinpflichtigem Typ-2-Diabetes. MEDIAS 2 Basis. Kirchheim, Mainz
Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand Å, Tisell A, Melander A (2000) Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43(5): 558–560
Patel A, MacMahon S, Chalmers J et al. (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24): 2560–2572
Turnbull FM, Abraira C, Anderson RJ et al. (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11): 2288–2298
UKPDS (1998a) UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853
UKPDS (1998b) UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865
Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130(5): 389–396
Literatur zu Abschn. 4.7
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaften der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 2. 2013, zuletzt geändert: September 2013, S 46–50.
http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie/pdf/NVL-DM2-Ther-lang-2.pdf. Zugriff 26 Jan 2014 DOI: 10.6101/AZQ/000170
DDG (2013) Deutsche Diabetes-Gesellschaft. Nationale VersorgungsLeitlinie. Therapie des Typ-2-Diabetes. 1. Aufl., Version 1, August 2013, AWMF-Register: Nr.: nvl-001g.
http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/NVL-DM2-Ther-lang_Endversion_270813.pdf. Zugriff 26 Jan 2014
Literatur zu Abschn. 4.8
Braun A et al. (2008) Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus. Patient Educ Couns 73(1): 50–59
Braun AK, Kubiak T, Kuntsche J, Meier-Höfig M, Müller UA, Feucht I, Zeyfang A (2009) SGS: a structured treatment and teaching programme for older patients with diabetes mellitus--a prospective randomised controlled multicentre trial. Age Ageing 38(4): 390–396
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365(21): 2002–2012
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Inzucchi SE, Bergenstal RM, Buse JB et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6): 1577–1596
Laiteerapong N, Karter AJ, Liu JY, Moffet HH, Sudore R, Schillinger D, John PJ, Huang ES (2011) Correlates of quality of life in older adults with diabetes – The Diabetes and Aging Study. Diabetes Care . 34 (8): 1749–1753
Levey AS, Greene T, Kusek JW, Beck GL (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11: 155A
Püllen R, Harhoff H-J, Nikolaus T, Oster P, Pfisterer M, Wernecke J, Zeyfang A (2010) Agaplesion Assessment Assistent Geriatrie. http://www.bethesda-stuttgart.de/Klinik-fuer-Innere-M.867.0.html (Downloads – AAA Geriatrie). Zugriff 26 Jan 2014
Roumie CL, Hung AM, Greevy RA et al. (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes. Ann Intern Med 157(9): 601–610
Schulz RJ, Kurtal H, Steinhagen-Thiessen E (2008) Rehabilitative Versorgung alter Menschen. In: Kuhlmey, Adelheid; Schaeffer, Doris (Hrsg) Alter, Gesundheit und Krankheit. Handbuch Gesundheitswissenschaften, 1. Aufl. Huber, Bern, S 1–21
Sinclair A, Morley JE, Rodriguez-Mañas L et al. (2012) Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. JAMDA 13 (6): 497–502
Zeyfang A (2005) Specific aspects of diabetes management in the elderly. MMW Fortschr Med 147(7): 37, 39–40
Zeyfang A, Bahrmann A, Wernecke J (2012b) Diabetes mellitus im Alter. Praxisleitlinie der Deutschen Diabetesgesellschaft. Diabetologie 7: S163–S169. http://www.deutschediabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Praxisleitlinien/2012/DuS_S2-12_Praxisempfehlungen_Zeyfang-etal_S163-169.pdf. Zugriff 26 Jan 2014
Zeyfang A, Berndt S, Aurnhammer G, Nikolaus T, Oster P, Bahrmann A (2012a) A short easy test can detect ability for autonomous insulin injection by the elderly with diabetes mellitus. J Am Med Dir Assoc 13(1): 81e 15–18
Weiterführende Internet-Links
http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Praxisleitlinien/Diabetes_mellitus_im_Alter_12.pdf. Zugriff 26 Jan 2014
http://www.diabetes-im-alter.de/. Zugriff 26 Jan 2014
http://www.diabetesstiftung.de/dial.0.html. Zugriff 26 Jan 2014
Literatur zu Abschn. 4.9
Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic ß-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 51: 2796–2803
Buse J (2000) Combining insulin and oral agents. Am J Med 108 (Suppl 6A): 23–32
Campbell IW (1985) Metformin an the sulphonylureas: the comparative risk. Horm Metab Rex 15 (Suppl): 105–111
Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M (1998) The STOP-NIDDm Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose toleranz: rationale, design, and preliminary screening data of the study to Prevent Non-Insulin- Dependent Diabetes Mellitus. Diabetes Care 21: 1720–1725
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group (2002) Acarbose for prevention ot type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 2072–2077
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose toleranz: the STOP-NIDDM trial. J AM Med Ass 290: 486–494
Cusi K, DeFronzo RA (1998) Metformin: a review of its metabolic effects. Diabetes Rev 6: 89–131
DeFronzo RA, Goofman AM and the Multicenter Metformin Study Group (1995) Efficacy of metformin in NIDDM patients poorly controlled an diet alone or diet plus sulfonylurea. N Engl J Med 333: 541–549
Dills DG, Schneider J and the Glimepirid/Glyburide Research Group (1996) Clinical evulation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 28: 426–429
Fölsch UR, Lembcke B (1991) Inhibition der intestinalen Alpha-Glukosidase in der Therapie des Diabetes mellitus. Internist 32: 699–707
Garber AJ, Dunacan TG, Goodman AM, Mills DJ, Rohlf JL (1997) Efficacy of metformin in type II diabetes: result of a double-blind, place-controlled, dose response trial. Am J Med 103: 491–497
Gribble FM, Reimann F (2003) Differential selectivity of insulin secretagogues. Mechanisms, clinical implications, and drug interactions. Diabetes Complications17 (Suppl 2): 11–15
Hansen JB (2006) Towards selective Kir6,2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem13: 61–376
Hansen AM, Christensen IT, Hansen JB et al. (2002) Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 51(9): 2789–2795
Häring HU, Joost HG, Laube H, Matthaei S, MeissnerHP, Panten U, Schernthaner G (2003) Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenzbasierte Diabetes-Leitlinien DDG. Diabetes Stoffwechsel 12 (suppl 2): 13–31
Hasslacher C (2003) Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renalfunction. Diabetes Care 26(3): 886–891
Holman RR, Cull CA, Turner RC (1999) A randomized double – blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years. Diabetes Care 22: 960–964
Holstein A, Plaschke A, Egberts EH (2001) Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated glimepride versus glibenclamid. Diabetes Metab Res Rev 17: 467–473
Holstein A, Plaschke A, Hammer C, Egberts EH (2003) Characteristics and time course of severe glimepiride – versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol 59(2): 91–97
Kahn SE, Haffner SM, Heise MA, Herman WH, Holmann RR, Jones NP, Kravitz BG, Lachin JM, O´Neill MC, Zinman B, Viberti G; ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23): 2427–2743
Knowler WC, Barrett-Conner, E Fowler SE, Hamman RF, Lachin JM, Walker, EA, Nathan DM, for the Diabetes Prevention Program Research Group. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403
Lebovitz H (1999) Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 diabetes. Review. Diabetes Care 22 (Suppl 3): C41–44
Luft D, Schmülling RM, Eggstein M (1978) Lactic acidose in biguanide-treated diabetics: a review of 330 cases. Diabetologia : 75–87
Matthaei S, Hamann A, Klein HH et al. (1991) Association of metformin´s effect to increase insulinstimulated glucose transport with potentiation of insulin-induced translocation of glucose transports form intracellular pool to plasma membrane in rat adipocyte. Diabetes 40: 850–857
Matthaei S, Hamann A (1993) Molekulare Mechanismen der antihyperglykämischen Wirkung von Metformin. Diabetes und Stoffwechsel 2: 307–314
Matthaei S, Stumvoll M, Kellerer M, Häring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Edocrine Rev 21: 585–618
Mertes G (1998) Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diabetes Res Clin Pr 40: 63–70
Müller G, Satoh Y, Geisen K (1995) Extrapanceratic effects of sulfonylureas – a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 28 (Suppl): 115–137
Navigator Studie Group, Holmann RR et.al. (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. Engl J Med 362(16): 1463–1476
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ et al. (2003) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46(3): 347–351
Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ (2005) Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 60: 208–217
Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett, K, Häring, HU (2002) Acute effect of glimepride on insulinstimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 25: 2065–2073
Patel A, MacMahon S, Chalmers J, Neal B, Billiot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Puulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F; ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24): 2560–2572
Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group (2004) Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27(6):1265–1270
Rote Hand Brief (2003) Kontraindikation zur gleichzeitigen Anwendung von Repaglinid (Handelsname NovoNorm®) und Gemfibrozil. 19-05-2003. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2003/90_20030519.pdf. Zugriff 10 März 2014
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use type 2 diabetes mellitus. Cochrane Database Syst Rev 4: CD002967. Doi; 10.1002/14651858.CD002967.pub4
Schramm TK et al. (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes with or without a previous myocardial infarction. A nationwide study. Eur Heart J DOI: 10.1093/eurheartj/ehr077
Standl E, Baumgartl HJ, Füchtenbusch M, Stemplinger J (1999) Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diab Obes Metab 1: 215–220
Stumvoll M, Nurjhab N, Perriello G, Dailey G, Gerich JE (1995) Metabolic effects of metformin in noninsulin-dependent diabetes mellitus. N Engl J Med 333: 550–554
Tuomilehto J, Lindstrom J, Eriksson JG et. al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350
UKPDS (1998) UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 584–865
Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkila M (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130: 389–396
Literatur zu Abschn. 4.10
Bosetti C, Rosato V, Buniato D et al. (2013) Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 18: 148–156
Bray GA et al. (2013) Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab 15(10): 913–917
Dormandy JA et al. on behalf of the PROactive Investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366: 1279–1289
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304: 411–418
Inzucchi SE, Bergenstal RM, Buse JB et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association fort he Study of Diabetes (EASD). Diabetes Care 35: 1364–1379
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G; ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427
Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones an d fractures in type 2 diabetes: a metaanalysis. CMJA 180: 32–39
Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR (2008) Use of thiazolidinediones and fracture risk. Arch Intern Med 168: 820
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471
Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170: 1191–1201
Literatur zu Abschn. 4.11
Anagnostis P, Athyros VG, Adamidou F et al. (2011) Glucagonlike peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 13: 302–312
Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131–2157
Best JH, Hoogwerf BJ, Herman WH et al. (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34: 90–95
Butler PC, Elashoff M, Elashoff R et al. (2013) A critical analysis of the clinical use o f Incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36: 2118–2125
Drucker DJ (2005) Biologic actions and therapeutic potential of the proglucagon -derived peptides. Nat Clin Pract Endocrinol Metab 1: 22–3. doi:10.1038/ncpendmet0017
Egan AG et al. (2014) Pancreatic safety of incretin-based drugs – FDA and EMA assessment. New Engl J Med 370: 794–797
Jose T, Inzucchi S E (2012) Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res 9: 109–116
Mundil D, Cameron-Vendrig A, Husain M (2012) GLP-1 receptor ag onists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9: 95–108
Nauck MA (20 09) Unraveling the science of incretin biology. Eur J Intern Med 20 Suppl 2: S303–308
Nauck MA (2013) A critical analysis of the clinical use of incretin- based therapies: the benefits by far outweigh the potential risks. Diabetes Care 36: 2125–2132
Nisal K, Kela R, Khunti K et al. (2012) Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med 10: 152
Scirica BM, Bhatt DL, Braunwald E et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14): 1317–1326
White WB Cannon CP, Heller SR et al. (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013 369(14): 1327–1335
Literatur zu Abschn. 4.12
Abdul-Ghani MA, Norton L, DeFronzo RA(2012) Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep 12(3): 230–238
Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10): 2217–2224
Hardman TC, Dubrey SW (2011) Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther 2(3): 133–145
Rosenstock J, Aggarwal N, Polidori D et al. (2012) Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35(6): 1232–1238
Stenlof K, Cefalu WT, Kim KA et al. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4): 372–382
Washburn WN (2012) Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opin Ther Pat 22(5): 483–494
Literatur zu Abschn. 4.13
ACCORD (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose l owering in type 2 diabetes. N Engl J Med.358(24): 2545–2559
ADVANCE (2008) The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T (2008) Once-daily basal insulin glargine versus thricedaily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371: 1073–1084
DECODE Study Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354: 617–621
EMA (2013) European Medicines Agency. Outcome of review of new safety data on insulin glargine Data from population- based studies and the scientific literature do not indicate an increased risk of cancer. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143823.pdf. Zugriff 16 Feb 2014
Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D (2012) Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35: 2402–2411 Garber AJ (2013) Treat-to-target trials: uses, interpretation, and review of concepts. Diabetes Obes Metab. doi: 10.1111/dom.12129
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Ryden LE, Yusuf S (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319–328
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15): 1577–1589
Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361: 1736-1747
Home PD (2012) The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 14: 780–788
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6): 1577–1596
Krssak M, Brehm A, Bernroider E, Anderwald C, Nowotny P, Dalla MC, Cobelli C, Cline GW, Shulman GI, Waldhausl W, Roden M (2004) Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53: 3048–3056
Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26: 881–885
Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, Jermendy G, Campaigne BN, Kerr L, Milicevic Z, Jacober SJ (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32: 381–386
Roden M (2009) Optimal insulin treatment in type 2 diabetes. N Engl J Med 361: 1801–1803
Literatur zu Abschn. 4.14 Ausgewählte Literatur
Holstein A, Beil W, Kovacs P (2012) CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opin Drug MetabToxicol 8: 1549–1563
Joost HG, Nauck M (2010) Diabetes mellitus. In: Lemmer B, Brune K (Hrsg) Pharmakotherapie Klinische Pharmakologie. Springer, Berlin Heidelberg, S 371–379
Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289: 1652–1658 Lebovitz HE (1999) Insulin secretagogues: old and new. Diabetes Rev 7: 139–146
Ritter CA, Klotz U, Kroemer HK (2010) Wechselwirkungen zwischen Arzneimitteln. In: Lemmer B, Brune K (Hrsg) Pharmakotherapie Klinische Pharmakologie. Springer, Berlin Heidelberg, S 469–477
Scheen AJ (2005) Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 28: 601–631
Literatur zu Abschn. 4.15
Astrup A et al. (2009) Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 374: 1606–1616
Brooks M (2013) FDA sides with EMA on incretin diabetes drugs. August 01, 2013
Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62(7): 2595–2604
Egan AG, Blind E, Dunder K et al. (2014) Pancreatic safety of incretin-based drugs – FDA and EMA Assessment. New Engl J Med 370: 794–797
Nainggolan L (2013) EU Agency has no new concerns on incretin diabetes drugs. July 26, 2013
Schatz H (2011) Antidiabetika in der Pipeline. Diabetes Forum Heft 4/2011, pp 32–37
Schatz H (2013a) Die GRADE-Studie: Welches Medikament als Kombinationspartner zu Metformin bei Typ-2-Diabetes? Kardiovaskuläre FDA-Outcome-Studien sinnlos? Beitrag im DGE-Blog vom 17. September 2013. http://blog.endokrinologie.net/date/2013/09/. Zugriff 16 Feb 2014 Schatz H (2013b) Innovationen in der Diabetesbehandlung: Neue Insuline. Diabetes aktuell 11(2): 60–66
Schatz H (2013c) Inkretin-Diabetesmedikamente: Kein Nachweis eines erhöhten Pankreatitisrisikos durch GLP-1- Analoga und Dipeptidylpeptidase-4-Hemmer. Beitrag im DGE-Blog vom 27. Juli 2013. http://www.blog.endokrinologie.net/date/2013/07/. Zugriff 6 März 2014
Schatz H (2013d)Herzinsuffizienz bei Diabetes bisher zu wenig beachtet: Relevant bei der Therapiewahl. Beitrag im DGE-Blog vom 27. September 2013 http://blog.endokrinologie.net/date/2013/09/. Zugriff 16 Feb 2014 Schatz H (2014) Herzinsuffizienzrisiko unter Saxagliptin wird von Amerikanischer Arzneibehörde FDA überprüft. Beitrag im DGE-Blog vom 13. Februar 2014. http://www. blog.endokrinologie.net/date/2013/02/. Zugriff 6 März 2014
Singh S, Chang H-Y, Richards TM et al. (2013) Glucagonlike peptide 1–based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population- based matched case-control study. JAMA Intern Med 173(7): 534–539. doi: 10.1001/jamainternmed. 2013.2720
Tucker ME (2013) Experts express mixed thoughts on canagliflozin approval. April 18, 2013
Viberti G, Kahn SE, Greene DA et al. (2002) A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes Diabetes Care 25 (10): 1737–1743. doi: 10.2337/ diacare.25.10.1737
Literatur zu Abschn. 4.16
Ammon HPT, Shehata AM (2011) Prevention of multiple low dose streptozotocin (MLD-STZ) induced diabetes in mice by extract from gum resin of Boswellia serrata and 11-keto-β-boswellic acids. Diabetologia 54 (Suppl 1): S 437
Leach MJ, Kumar S (2012) Cinnamon for diabetes mellitus. Cochrane Database Syst Rev 9:CD007170
Loopstra-Masters RC, Liese AD, Haffner SM, Wagenknecht LE, Hanley AJ (2011) Associations between the intake of caffeinated and decaffeinated coffee and measures of insulin sensitivity and beta cell function. Diabetologia 54:320–328
Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS (2003) Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26: 1277–1294
Literatur zu Abschn. 4.17
Autier P, Boniol M, Pizot C, Mullie P (2014) Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2(1): 76–89
Avenell A et al. (2011) J Clin Endocrinol Metabol DOI:10.1210jc.2011–1309
Binkley N et al. (2010) Clin Chim Acta 411: 1976–1982
Bjelakovic G et al. (2011) The Cochrane Library, Issue 7
DGE (2012) Deutsche Gesellschaft für Endokrinologie. Pressemitteilung der DGE vom 25.01.2012. http://www.endokrinologie.net/presse_120125.php. Zugriff 19 Feb 2014
Holick MF et al. (2011) J Clin Endocrinol Metabol, published online June 6, 2011
Linseisen et al. (2012) http://www.dge.de/pdf/ws/DGEStellungnahme-VitD-111220
Mei Chung et al. (2011) Ann Intern Med 155 :827–838
Sattar N et al. (2012) Lancet 379: 95–96
Shapes SA et al. (2011) JAMA 305: 2565–2566
Literatur zu Abschn. 4.18
Aterburn DE, Bogart A, Sherwood NE et al (2013) A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 23: 93–102
Buchwald H, Avidor Y, Braunwald E et al. (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292: 1724–1737
Carlsson LMS, Peltonen M, Ahlin S et al. (2012) Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. NEJM 367: 695–704
Chang SH, Stoll CR, Song J et al. (2013) The effectiveness and risks of bariatric surgery. An updated systematic review and meta-analysis, 2003–2012. JAMA Surg. doi:10.1001/ jamasurg.2013.3654
Laferre B, Heshka S, Wang K et al. (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30: 1709–1716
Leroy J, Ananian P, Rubino F et al. (2005) The impact of obesity on technical feasibility and postoperative outcomes of laparoscopic left colectomy. Ann Surg 241(1): 69–76
Moran-Atkin E, Brody F, Fu SW, Rojkind M (2013) Changes in GIP gene expression following bariatric surgery. Surg Endosc 27(7): 2492–2497
Runkel N, Colombo-Benkmann M, Hüttl TP et al. (2011) Bariatric surgery. Dtsch Ärztebl 108(20): 341–346
Sjöström L (2013) Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Int Med 273(3): 219–234
Thaler JP, Cummings DE (2009) Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 150(6): 2518–2525
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ammon, H. et al. (2014). Typ-2-Diabetes. In: Schatz, H., Pfeiffer, A. (eds) Diabetologie kompakt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41358-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-41358-2_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-41357-5
Online ISBN: 978-3-642-41358-2
eBook Packages: Medicine (German Language)